Pregnancy and Crohn’s disease:concerns and assurance of medical therapy  

作　　者：Reezwana Chowdhury Sunanda V.Kane 

机构地区：[1]Division of Gastroenterology and Hepatology,Department of Medicine,Johns Hopkins University,Baltimore,MD,USA [2]Division of Gastroenterology and Hepatology,Department of Medicine,Mayo Clinic,Rochester,MN,USA

出　　处：《Gastroenterology Report》2022年第1期171-177,共7页胃肠病学报道（英文）

摘　　要：Approximately 50%of patients with inflammatory bowel disease including both Crohn’s disease and ulcerative colitis are female with many being diagnosed and treated during their reproductive years.It is important for women to be in remission prior to and during pregnancy.There have been many advances in the treatment of inflammatory bowel disease,including new therapies.In this review,we summarize the currently approved medications for Crohn’s disease and their safety in pregnancy and postpartum.The totality of evidence suggests that the majority of therapies are low-risk before and during pregnancy,and should be continued to control maternal disease.

关 键 词：Crohn’s disease PREGNANCY TERATOGENICITY inflammatory bowel disease LACTATION BIOLOGICS ANTI-TNF 

分 类 号：R574.62[医药卫生—消化系统]